Market Overview

ARIAD Announces Analysis of Cardiovascular Risk Profile of Patients in Pivotal PACE Trial of Iclusig

ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of
evaluation of the cardiovascular risk profile of Philadelphia-positive
(Ph+) leukemia patients treated with Iclusig® (ponatinib) in
the pivotal PACE trial. Serious arterial thrombotic (AT) events can be a
complication of BCR-ABL tyrosine kinase inhibitor (TKI) therapy in Ph+
leukemias. In the single-arm, PACE trial, serious AT events, including
cardiovascular, cerebrovascular and peripheral vascular events, occurred
in 34 of 449 patients (8%). This analysis showed that patients who
experienced serious ATs while on study more commonly had a history of
pre-existing cardiac disease and a higher prevalence of baseline
cardiovascular risk factors prior to enrollment than in those patients
who did not experience these events.

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters